

Modeling of Quinoacridinium Derivatives as Antitumor Agents using a QSAR analysis

Ruslin Hadanu

Department of Chemistry Education, Faculty of Teacher Training and Education Science, Universitas Sembilanbelas November Kolaka, Jl. Pemuda No. 339 Kolaka, Sulawesi Tenggara 93517, Indonesia

Info Article

Submitted: 29-02-2019

Revised: 23-05-2019

Accepted: 19-06-2019

*Corresponding author
Ruslin Hadanu

Email:
ruslinhadanu@gmail.com

ABSTRACT

A QSAR analysis has been performed on a compound series of 1-11 quinoacridinium derivatives as internal test compounds, and compounds of 12-15 quinoacridinium derivatives as external test compounds. The electronic descriptors used in this study were atomic net charge (q), dipole moment (μ), E_{LUMO} , E_{HOMO} , polarizability (α), and Log P. They were calculated through HyperChem for Windows 8.0 software using semi-empirical PM3 method. The antitumor activity (IC_{50}) of quinoacridinium derivative compounds was obtained from literature. Furthermore, the model of QSAR equation was analyzed through RML method which produced the best QSAR equation model: $\text{Log } IC_{50} = -13.010 + 15.338(qC3) - 4.31(qC4) - 155.308(qC9) + 33.626(qC11) + 26.626(qC12) + 24.631(qC14) - 0.228(\mu) - 0.621(E_{LUMO}) - 0.066(\alpha) + 0.233(\text{Log } P)$. The model of QSAR equation has a correlation coefficient $n = 11$, $(r) = 1.00$, $(r^2) = 1.00$, $SE = 0$, and $PRESS = 0.003$. Among 28 compounds of quinoacridinium derivative which were designed, only 15 compounds, namely 16, 19-20, 22-28, 30-32, 39, and 40 compounds, have been recommended to be synthesized in the laboratory.

Key words: quinoacridinium derivatives, QSAR analysis, anti-tumor, PM3 method, MLR analysis

INTRODUCTION

Tumors and cancers still become dangerous health problem in the world because of their high morbidity and mortality. In 2012, there were 14.1 million new cancer cases, with 8.2 million cancer deaths (Torre *et al.*, 2015). In 2000, productivity costs which was lost due to cancer deaths were 115.8 billion US dollars, and by 2020, these costs are predicted to reach 147.8 billion US dollars (Bradley *et al.*, 2008). The main problems in a cancer therapy are low selectivity and high toxicity. Therefore, it is necessary to develop antitumor drugs with high selectivity as well as low toxicity, so that the therapy will be more effective. One of the antitumor compounds that has been widely studied and continuously developed by previous researchers is the derivatives of acridinium compounds.

A recent study on acridinium derivatives was conducted in 2008 (Cheng *et al.*, 2008). It was a synthesis on a series of salt-derivative compound with 8,13-dimethylquino[4,3,2-kl]acridinium as an antitumor. Derivatives of the acridinium

compounds used as an antitumor have been studied (Cooksonet *et al.*, 2005). Research on the derivatives of acridine compounds has been done by various researchers since 1984. They isolated acridine compounds from plant species, *Lactariusnecator* (Agaricales) (Fugmann *et al.*, 1984). Furthermore, after 13 years later, the ring of acridine compounds was successfully synthesized and antitumor activity was tested (Hagan *et al.*, 1997). After that in 1998, several researchers conducted a study to convert 9-azidoacridine to 7H-pyrido [4,3,2-kl]acridine compound and succeeded in changing the pyridine ring to 7H-pyrido[4,3,2-kl]acridine compound to increase the antitumor derivative activity of acridine compounds (Hagan *et al.*, 1998; Julino & Stevens, 1998). In 2000, the ring of acridine compound was developed into *tetra*-, *penta*-, and *hexacyclic* rings in a heteroaromatic system through a cyclical process of 9-anilinoacridineto enhance antitumor activity of derivatives of acridine compounds which were synthesized in the previous years (Stanslas *et al.*, 2000; Ellis *et al.*, 2001).

Research on the derivatives of acridine compounds continues being developed by researchers. Some of them are the synthesis of acridine polycyclic compounds, i.e. 8,13-diethyl-6-methylquino[4,3,2-kl]acridinium iodide and 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (Missailidis *et al.*, 2002; Leonetti, 2004). The synthesis of the acrylic polycyclic derivative was intended to increase the antitumor activity and the solubility of the compound (Missailidis *et al.*, 2002; Leonetti, 2004). Efforts to obtain a more active antitumor through the derivatives of acridine compounds were continued by researchers through the synthesis of more polar and complex compounds using the alkylation method of polycyclic acridine compounds (Cookson *et al.*, 2005). The development of antitumor compounds from polycyclic acridine has been carried out (Cheng *et al.*, 2008). It is a salt compound of 8,13-dimethylquino[4,3,2-kl]acridinium and has an antitumor activity (IC₅₀) around 0.21 to 2.00 μ M. The salt compound which has the highest activity is derivatives of 8,13-dimethylquino[4,3,2-kl]acridinium which is bound up both with anionic iodine and an ester functional group on C2 atom of such cyclic compound ring. Antitumor activity of salt derivatives 8,13-dimethylquino[4,3,2-kl]acridinium compound is still low when it is compared with antitumor compounds that have been circulating in the market (Cheng *et al.*, 2008). Based on the results of the research above, the efforts to develop antitumor compounds from other compounds have also been developed recently, such as o-isoselenazolon, and gallium-pyridine complexes known as metal-based drugs with a very high anticancer activity (Schmitt & Dou, 2013; Florea & Büsselberg, 2011; Luo *et al.*, 2012). However, the development of an anticancer compound from heavy metals causes many metabolic risks to the human body. Other studies on anticancer and antitumor have also been done by many researchers (Miladiyah *et al.*, 2016; Hosny *et al.*, 2012; Alam *et al.*, 2016; Reddy *et al.*, 2012; Bladt *et al.*, 2013; Heliawati *et al.*, 2015; Noolvi and Patel, 2013; Deep *et al.*, 2016; Shelton *et al.*, 2016; Tripodi *et al.*, 2012; Su *et al.*, 2011). They consecutively isolated and modified the chemical structures on the following compounds: (1) derivatives of benzoylphenylurea; (2) derivatives of *N*-benzoyl cephalixin; (3) derivatives of benzoyl paracetamol mercaptotriazoles; (4) derivatives of coumarin and quinoliny; (5) sesquiterpenecoumarin; (6) derivatives of tri-terpenoide

saponin; (7) extracts of *Acalypha indica* leaf; (8) derivatives of polyketide; (9) extracts of *Scaevola spinescens*; (10) extracts from the *Coryphaea lamk*; (11) derivatives of polyketide; (12) derivatives of 2,3,7-trisubstituted quinazoline; (13) derivatives of 2-azetidinone; (14) derivatives of glutathione; (15) derivatives of nucleoside and nucleotide; (16) derivatives of 1,4-diaryl-2-azetidinones; and (17) xanthone derivative compounds (Miladiyah *et al.*, 2016; Hosny *et al.*, 2012; Alam *et al.*, 2016; Reddy *et al.*, 2012; Bladt *et al.*, 2013; Heliawati *et al.*, 2015; Noolvi & Patel, 2013; Deep *et al.*, 2016; Shelton *et al.*, 2016; Tripodi *et al.*, 2012; Su *et al.*, 2011). The antitumor activities of all compounds afore mentioned before are still low when they are compared with antitumor compounds that have been circulating in the market. All compounds which were isolated and modified generally have a functional group of primary amine (-NH₂). Based on the results of the research above, to design the structure of antitumor or anticancer molecules, it is necessary to make a model of anticancer molecules whose structures are cyclic compounds and have functional groups of amine (-NH₂). In this study it was attempted to synthesize quinoacridinium derivative compounds that have an amine functional group, so that they are antitumor compounds that meet this criterion.

Based on the explanation above, the effort to find an antitumor compound from the 8,13-dimethylquino[4,3,2-kl]acridinium which has a functional group -NH₂ is still very potential to be a candidate for antitumor drugs which are expected to have activity high and friendly to the body. Efforts to develop an antitumor drug from 8,13-dimethylquino[4,3,2-kl]acridinium derivatives need to be done through a computational chemistry approach with a Quantitative Structure-Activity Relationship (QSAR) analysis to obtain more active and body-friendly compounds. The QSAR analysis is one of the latest methods in the phases of developing new drugs. The results of QSAR analysis are generally used as a guide to design new drugs theoretically. In this study, the results of QSAR analysis are used as guidance in designing compounds of 8,13-dimethylquino[4,3,2-kl]acridinium derivatives that are potentially to be antitumor and have never been previously synthesized. The QSAR analysis approach as an effort to design drug compounds is very important because it minimizes the use of chemicals and energy. It also saves time because it can avoid trial and error experiments in laboratory.

However, it can still provide a relatively high level of confidence (Hadanu and Syamsudin, 2013). The QSAR analysis aims to find an empirically consistent relationship between the molecular properties and the biological activity of a series of homologous structural compounds of the drug. The QSAR study began to grow rapidly after 1960. It was pioneered by Corwin Hansch who connected chemical structures with drug biology activities through common chemical-physical properties such as fat solubility, ionization degree, and molecular size. Later on in the last few decades, it was developed more intensively into a quantitative relationship between biological activity and various chemical-physical parameters such as net atomic charge, $E_{LUMO}-E_{HOMO}$, solubility in fat (polarisabilities), solubility in water and alcohol (Log P), molecular size, hydrophobic parameters, electronics and sterics in a series of molecules (Hadanu and Syamsudin, 2013). The relationship between physical as well as chemical properties and biological activity is proposed by (Ferguson *et al.*, 1997) with an equation that can be used to relate some activity data with the following parameters:

$$\text{Log BR} = f(P_1, P_2, P_3) \dots \dots \dots (1)$$

BR (Biological Response) is a biological activity or biological response as an algebraic function of 3 parameters P_1 , P_2 , and P_3 which is the nature of the structure under investigation. The development of QSAR analysis in the next period uses the net charge of the atom as an estimator and expressed by:

$$\text{Log BR} = \sum_i P_i q_i + C \dots \dots \dots (2)$$

P_i is the fitting parameter for i^{th} atom, and q_i is the net charge of the atoms and other parameters for the i^{th} atom and C is constant. In the development of subsequent research, QSAR study is very helpful in the search for new drugs with greater activity, higher selectivity, toxicity or minor side effects, and greater comfort. In addition, using the QSAR equation model can save more money because to get a new drug with high activity, the experimental factor can be minimized as much as possible (Hadanu *et al.*, 2015).

Some attempts at cancer treatment have been performed in various ways such as surgery, radiation, anticancer drug treatment or chemotherapy. However, these efforts have not achieved satisfying results; even the effects of surgical failure can cause cancer to spread to other

parts of the body with severe conditions (Nugraha *et al.*, 2018). This encourages the development of new medicine from 8,13-dimethylquino[4,3,2-kl]acridinium compound which is more active, friendly to the body, and expectedly to have a good therapeutic effect.

MATERIAL AND METHODS


The materials used in this study were quinoacridinium derivative compounds that have been synthesized by Cheng *et al.*, (2008). Inhibition Concentration (IC_{50}) was used as the dependent variable (Table I and II) (Cheng *et al.*, 2008).

Instrumentation

In this study, the tools used for QSAR test were computer hardware devices namely a Sony Vaio Laptop with Intel® Dual Core Processor 2.20 GHz; 1 GHz RAM, and HDD 250 GB. Meanwhile, the software used in this study is HyperChem 8.0 for Windows for optimization purposes of 3D structure and geometry optimization of the chemical structure of tested compounds (compounds 1-11), external test compounds (compounds 12-15) and the structure of quinoacridinium derivative compounds (compound 16-43). For statistical analysis to obtain the QSAR equation, SPSS 19.0 for Windows was used.


Calculating the descriptors

Internal fitting compounds (Table I), external fitting compounds (Table II), and modeling compounds (Table V) were constructed respectively in three-dimensional (3D) structures with the HyperChem 8.0 for Windows programming package. Furthermore, the geometric structures of all fitting compounds and model compounds were optimized to obtain more stable structural conformation using the semi-empirical PM3 method. This method is chosen because semi-empirical methods can be performed descriptor calculations quickly and accurately. The semi-empirical method is faster than the ab-initio method although it is less accurate and the semi-empirical method is more accurate than the AM1 method even though it is slower than the AM1 method. In addition, semi-empirical methods are methods that use experimental and theoretical data sets. When viewed with the molecular structure used, semi-empirical methods are suitable, because the quinoacridinium molecule have a medium molecular weight and functional groups $-NH_2$, $-NHR$, and $-NR_2$.

Table I. Chemical structure and activity data of antitumor compounds of quinoacridinium derivatives obtained from Cheng *et al.*, (2008)


The chemical structure shows a quinoacridinium cation with a central nitrogen atom (N13) carrying a positive charge, balanced by an anion X⁻. The structure consists of three fused ring systems: a central benzene ring (positions 12-19) and two flanking benzene rings (positions 1-11 and 14-21). Various positions are substituted with R groups (R¹ to R¹³, R², R³, R⁶, R⁸, R¹⁰, R¹¹, R¹³, R⁹, R⁷, R⁵, R⁴, R³). The numbering of the atoms is as follows: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21.

Compounds	R ²	R ³	R ⁶	R ⁸	R ¹⁰	R ¹¹	R ¹³	X ⁻	IC ₅₀ (μM)	Log IC ₅₀
1	H	H	CH ₃	C ₂ H ₅	H	H	C ₂ H ₅	I ⁻	2.00	0.30
2	H	CH ₃	CH ₃	CH ₃	H	CH ₃	CH ₃	H ₃ COSO ₃ ⁻	0.25	-0.60
3	H	H	CH ₃	CH ₃	H	H	CH ₃	H ₃ COSO ₃ ⁻	0.74	-0.13
4	H	H	H	CH ₃	H	H	CH ₃	I ⁻	1.55	0.19
5	NHCOCH ₃	H	H	CH ₃	H	H	CH ₃	I ⁻	0.38	-0.42
6	NHCOCF ₃	H	H	CH ₃	H	H	CH ₃	I ⁻	0.31	-0.51
7	NHCO(CH ₂) ₄ CO ₂ CH ₃	H	H	CH ₃	H	H	CH ₃	I ⁻	0.21	-0.68
8	N(CH ₃)SO ₂ C ₆ H ₄ -p-F	H	H	CH ₃	H	H	CH ₃	I ⁻	0.73	-0.14
9	H	NHCOCH ₃	H	CH ₃	H	H	CH ₃	I ⁻	0.41	-0.39
10	H	Cl	OCH ₃	CH ₃	H	H	CH ₃	I ⁻	0.28	-0.55
11	H	CH=CHCON(CH ₂ CH ₂) ₂ O	H	CH ₃	H	H	CH ₃	I ⁻	0.37	-0.43

Table II. The chemical structure of external standard compounds of quinoacridinium derivatives from Cheng *et al.*, (2008).


The chemical structure is identical to the one in Table I, showing a quinoacridinium cation with a central nitrogen atom (N13) carrying a positive charge, balanced by an anion X⁻. The structure consists of three fused ring systems: a central benzene ring (positions 12-19) and two flanking benzene rings (positions 1-11 and 14-21). Various positions are substituted with R groups (R¹ to R¹³, R², R³, R⁶, R⁸, R¹⁰, R¹¹, R¹³, R⁹, R⁷, R⁵, R⁴, R³). The numbering of the atoms is as follows: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21.

Compounds	R ²	R ³	R ⁶	R ⁸	R ¹⁰	R ¹¹	R ¹³	X ⁻	IC ₅₀ (μM)	Log IC ₅₀
12	H	F	CH ₃	CH ₃	H	F	CH ₃	H ₃ COSO ₃ ⁻	0.33	-0.48
13	NH ₂	H	H	CH ₃	H	H	CH ₃	I ⁻	1.86	0.27
14	NHCOC(CH ₃) ₃	H	H	CH ₃	H	H	CH ₃	I ⁻	0.23	-0.64
15	H	Cl	H	CH ₃	H	H	CH ₃	I ⁻	0.26	-0.59

The structural optimization was performed by using Polak-Ribiere algorithm optimization method with RMS value = 0.001 kcal/(Å.mol), which was recorded through the single point menu. Via the data from the single point menu, the electronic parameters such as the net atomic charge, the dipole moment (μ), the polarization (α), and the Log P were obtained. Meanwhile, the E_{LUMO} and the E_{HOMO} were obtained from compute and orbital menus which were presented (Table III and IV). The selection of descriptor type was adjusted

to the type of descriptor used by Motta *et al.*, (2006) in conducting QSAR analysis. The structure of the quinoacridinium derivative compounds as the study material was calculated by involving an ion counter of salt.

QSAR equation analysis by using a linear regression method

The dependent variable in this study was the antitumor activity with IC₅₀ value based on experiment (Table I), while the independent

Table III. Log IC₅₀ experiments and Log IC₅₀ calculated of external test compounds

Compounds	Log IC ₅₀ experiments	Log IC ₅₀ calculated
12	-0.48	-0.359
13	0.27	0.166
14	-0.64	-0.602
15	-0.59	-0.589

Table IV. Descriptors/independent variables used for QSAR analysis of antitumor compounds of quinoacridinium derivatives calculated by the semi-empirical PM3 method

Comp.	Atomic net charges (Coulomb)												
Number	qC1	qC2	qC3	qC4	qC5	qC6	qC7	qN8	qC9	qC10	qC11	qC12	qN13
1	-0.075	-0.060	-0.077	-0.083	-0.160	0.033	-0.193	0.200	-0.179	-0.015	-0.112	-0.039	0.200
2	-0.056	-0.072	-0.038	-0.095	-0.153	0.023	-0.187	0.188	-0.165	-0.034	-0.062	-0.054	0.523
3	-0.069	-0.067	-0.073	-0.090	-0.155	0.024	-0.189	0.188	-0.182	-0.025	-0.114	-0.073	0.491
4	-0.019	-0.077	-0.064	-0.098	-0.145	-0.015	-0.179	0.170	-0.170	-0.030	-0.124	-0.046	0.573
5	-0.139	-0.014	-0.126	-0.054	-0.153	0.001	-0.187	0.194	-0.175	-0.017	-0.115	-0.042	0.458
6	-0.052	-0.058	-0.104	-0.066	-0.146	-0.010	-0.179	0.175	-0.170	-0.026	-0.124	-0.044	0.558
7	-0.152	-0.015	-0.131	-0.050	-0.144	-0.017	-0.178	0.187	-0.173	-0.031	-0.115	-0.057	0.420
8	-0.207	0.087	-0.138	-0.042	-0.156	0.002	-0.187	0.189	-0.176	-0.017	-0.115	-0.029	0.453
9	-0.065	-0.095	-0.043	-0.131	-0.138	-0.022	-0.171	0.187	-0.170	-0.033	-0.111	-0.060	0.432
10	-0.003	-0.081	-0.099	-0.101	-0.191	0.178	-0.264	0.171	-0.168	-0.030	-0.122	-0.045	0.562
11	-0.086	-0.074	-0.038	-0.064	-0.139	-0.020	-0.174	0.189	-0.172	-0.032	-0.111	-0.060	0.416

Comp.	Atomic net charges (Coulomb)								μ	E _{LUMO}	E _{HOMO}	α	Log P
Number	qC14	qC15	qC16	qC17	qC18	qC19	qC20	qC21	(Debye)	(ev)	(ev)	(Å ³)	
1	-0.126	-0.052	0.067	0.073	-0.145	-0.145	-0.019	0.012	20.946	-2.563	-4.236	46.27	2.12
2	-0.161	-0.025	0.052	0.017	-0.127	-0.120	-0.043	0.003	18.287	-2.291	-8.730	45.49	0.94
3	-0.154	-0.040	0.057	0.037	-0.136	-0.141	-0.031	0.005	16.840	-2.252	-8.784	41.82	0.63
4	-0.124	-0.033	0.056	0.000	-0.113	-0.119	-0.025	-0.010	13.352	-2.078	-5.712	40.77	1.28
5	-0.115	-0.079	0.070	0.049	-0.135	-0.139	-0.022	-0.003	15.507	-2.541	-4.590	45.88	-0.61
6	-0.098	-0.049	0.060	0.018	-0.119	-0.124	-0.024	-0.008	14.899	-2.311	-5.323	45.60	0.50
7	-0.094	-0.065	0.048	-0.005	-0.100	-0.112	-0.029	-0.015	12.513	-2.478	-5.327	55.77	0.00
8	-0.083	-0.084	0.077	0.074	-0.134	-0.139	-0.022	0.001	15.889	-2.456	-4.310	54.66	-0.56
9	-0.149	-0.008	0.028	-0.014	-0.091	-0.107	-0.031	-0.017	14.072	-2.604	-5.459	45.88	-0.61
10	-0.121	-0.028	0.087	0.016	-0.150	-0.117	-0.028	0.031	15.096	-2.151	-5.098	45.17	0.06
11	-0.127	-0.033	0.035	-0.007	-0.094	-0.108	-0.030	-0.017	15.213	-2.558	-5.367	54.72	0.36


variables used were net atomic charges, dipole moment (μ), E_{LUMO} , E_{HOMO} , polarizability (α), and Log P (Tables III and IV). All variables were analyzed using enter method through MLR to find out which sequence of independent variables influenced the antitumor activity value of quinoacridinium derivative compounds. The result generated QSAR equations as well as statistical parameters such as r , r^2 , SE, and PRESS values. In addition to the statistical parameters, the calculation result also obtained the constant value and the coefficient value of each independent variable involved in the equation result. The

obtained coefficient value was used to calculate the theoretical antitumor activity (IC₅₀ theoretical value) toward quinoacridinium derivative compounds. Furthermore, after finding out the square difference between the IC₅₀ experimental value and the IC₅₀ theoretical value, the PRESS value can be calculated to know the quality and prediction ability of the best equation of the QSAR model.

Design of new antitumor molecules

The design of new antitumor drug molecules in this study was aimed to discover novel


Table VI. The New designed quinoacridinium derivatives as antitumor compounds



Compounds	Substituents				
	R ²	R ³	R ⁶	R ⁸	R ¹⁰
16	H	Cl	CH ₃	CH ₃	H
17	NHCH ₃	H	H	CH ₃	H
18	N(CH ₃) ₂	H	H	CH ₃	H
19	NHCOC ₄ H ₉	H	H	CH ₃	H
20	NHCOC ₁₁ H ₂₃	H	H	CH ₃	H
21	NHCO ₂ C ₂ H ₅	H	H	CH ₃	H
22	NHCOPh	H	H	CH ₃	H
23	H	H	OCH ₃	CH ₃	Cl
24	H	H	OCH ₃	CH ₃	CH=CHCON(CH ₂ CH ₂) ₂ O
25	H	H	OCH ₃	CH ₃	CH=CHCO ₂ CH ₃
26	H	H	(CH ₂) ₃ OCOCH ₃	CH ₃	(CH ₂) ₃ OCOCH ₃
27	H	Cl	CH=CHCON(CH ₂ CH ₂) ₂ O	CH ₃	H
28	H	CH=CHCON(CH ₂ CH ₂) ₂ O	OCH ₃	CH ₃	H
29	H	CH=CHCON(CH ₂ CH ₂) ₂ O	(CH ₂) ₃ OCOCH ₃	CH ₃	H
30	H	(CH ₂) ₃ OCOCH ₃	(CH ₂) ₃ OCOCH ₃	CH ₃	H
31	H	Cl	CH ₃	CH ₃	H
32	H	Cl	CH ₃	C ₂ H ₅	H
33	N(C ₂ H ₅) ₂	H	H	CH ₃	H
34	N(C ₂ H ₅) ₂	H	H	C ₂ H ₅	H
35	NHCOC ₃ H ₇	H	H	C ₃ H ₇	H
36	NHCOC ₂ H ₅	H	H	C ₂ H ₅	H
37	NHCOC ₁₁ H ₂₃	H	H	C ₂ H ₅	H
38	NHCOPh	H	H	C ₂ H ₅	H
39	H	H	(CH ₂) ₃ OCOCH ₃	C ₂ H ₅	(CH ₂) ₃ OCOCH ₃
40	H	Cl	CH=CHCON(CH ₂ CH ₂) ₂ O	C ₂ H ₅	H
41	H	CH=CHCON(CH ₂ CH ₂) ₂ O	OC ₂ H ₅	C ₂ H ₅	H
42	H	CH=CHCON(CH ₂ CH ₂) ₂ O	(CH ₂) ₃ OCOCH ₃	C ₂ H ₅	H
43	H	(CH ₂) ₃ OCOC ₂ H ₅	(CH ₂) ₃ OCO C ₂ H ₅	C ₂ H ₅	H

compounds of quinoacridinium derivatives which have higher antitumor activity than previously synthesized compounds. The molecular design was performed by varying the type and position of substituent or functional group positions in the main framework structure of quinoacridinium derivative compounds. The substituent position was focused on the active center area by considering the feasibility of synthesis in the laboratory. The substituent or functional group is

the dominantly responsible atoms of the antitumor activity of the quinoacridinium derivatives. After finding out the quinoacridinium molecular sequence series, the next step is calculating the descriptor of the new compound of modeling design (Table VI and VII) by using the semi-empirical method of PM3 using HyperChem 8.0 for Windows. Based on the best QSAR equations, we can calculate the theoretical antitumor activity of the design compounds (Table VI and VII).

Table VII. Predicted Log IC₅₀ calculated using the best QSAR model

Compounds	Substituents			Predicted Log IC ₅₀	Predicted IC ₅₀
	R ¹¹	R ¹³	X ⁻		
16	Cl	CH ₃	H ₃ COSO ₃ ⁻	-5.692	0.000002
17	H	CH ₃	I ⁻	-0.111	0.775149
18	H	CH ₃	I ⁻	0.080	1.201752
19	H	CH ₃	I ⁻	-0.901	0.125555
20	H	CH ₃	I ⁻	-0.760	0.173970
21	H	CH ₃	I ⁻	-0.315	0.484069
22	H	CH ₃	I ⁻	-0.894	0.127722
23	H	CH ₃	I ⁻	-1.036	0.091970
24	H	CH ₃	I ⁻	-3.928	0.000118
25	H	CH ₃	I ⁻	-3.400	0.000398
26	H	CH ₃	I ⁻	-1.743	0.018086
27	H	CH ₃	I ⁻	-1.254	0.055728
28	H	CH ₃	I ⁻	-0.910	0.122898
29	H	CH ₃	I ⁻	-0.040	0.912860
30	H	CH ₃	I ⁻	-1.460	0.034668
31	Cl	C ₂ H ₅	H ₅ C ₂ OSO ₃ ⁻	-5.414	0.000004
32	Cl	C ₂ H ₅	H ₅ C ₂ OSO ₃ ⁻	-1.745	0.017990
33	H	C ₂ H ₅	I ⁻	0.522	3.327068
34	H	C ₂ H ₅	I ⁻	0.955	9.013149
35	H	C ₃ H ₇	I ⁻	-0.329	0.468765
36	H	C ₂ H ₅	I ⁻	0.847	7.031945
37	H	C ₂ H ₅	I ⁻	0.001	1.001424
38	H	C ₂ H ₅	I ⁻	-0.113	0.770079
39	H	C ₂ H ₅	I ⁻	-1.391	0.040617
40	H	C ₂ H ₅	I ⁻	-0.805	0.156537
41	H	C ₂ H ₅	I ⁻	2.139	137.657528
42	H	C ₂ H ₅	I ⁻	-0.699	0.200199
43	H	C ₂ H ₅	I ⁻	0.093	1.237455

RESULT AND DISCUSSION

The stages of quantitative relationship analysis of structures carried out in this study were (a) determining series of quinoacridinium compounds which had IC₅₀ values based on experiment in the laboratory Cheng *et al.*, (2008); (b) optimizing the basic structural framework of the most stable quinoacridinium derivative as the initial compound in the process of optimizing the test compound for further analysis; (c) determining descriptor (independent variable); (d) calculating

descriptor through optimization structure of tested compounds (optimization of derivative structure of tested compound) (Table I and II); (e) performing correlation analysis between variables through bivariate correlation method; (f) performing multilinear regression analysis to obtain the model of QSAR equation; (g) determining the best QSAR equation model (Hadanu and Syamsudin, 2013; Hadanu *et al.*, 2015) and (h) designing a new compound of quinoacridinium derivatives based on the best QSAR equation model.




Figure 1. Correlation between Log IC₅₀ calculated from the internal test compound and Log IC₅₀ experiment




Figure 2. Correlation between Log IC₅₀ of the external test compound and Log IC₅₀ experiment

The quinoacridinium derivative compounds as the materials in this study has the following requirements: (1) the basic framework structure of the homologous compound should be possessed by all fittings compounds, external test compounds, and the modeled compound; (2) the fitting compound; and (3) the external test compound should have IC₅₀ value which is experimented in a laboratory. The optimization of the structures of all fitting compounds, external test compounds, and the modeled compounds was carried out by the same method to obtain the most stable structural compound with the lowest energy profile. When all of compound structures are at the lowest profile energy, they are in the most stable condition. In that condition, the descriptor (independent variable) required in the next stage of QSAR analysis can be obtained.

By bivariate correlation analysis, it is clear that the variables of atomic net charge, dipole moment (μ), $E_{\text{HOMO-ELUMO}}$, polarisabilities (α), and Log P showed a very close correlation. This is indicated by the absolute value of the correlation which is closer to 1 or -1. The evidence of such close correlation can be seen in some of the relationships between descriptors that have a high correlation, for example: the correlation between variables QC1-QC2 (-0.893), qC6-qC5 (-0.898), QC2-qC4 (0.774), qC7-qC5 (0.994), qC5-QC10 (-0.754), qC6-qC7 (-0.920), QC1-qC15 (0.823), QC2-qC15 (-0.865), QC3-qC14 (-0.825), QC3-qC15 (0.831), qC4-qC14 (0.773), qC4-qC15 (-0.897), qN8-qN13 (-0.837), qC5-qC16 (-0.820), qC5-qC17 (-0.913), qC5-qC18 (0.961), qC5-qC19 (0.910), qC6-qC17 (0.724), qC6-qC18 (-0.863), qC6-qC19 (-0.766), qC7-qC16 (-0.791), qC7-qC17 (-0.890),

qC7-qC18 (0.963), qC7-qC19 (0.906), QC1- α (-0.759), qC5-qC21 (-0.961), qC5- μ (-0.764), qC6-qC21 (0.968), qC6- μ (0.903), qC7- qC21 (-0.967), qC7- μ (-0.778), and qN8-ELUMO (-0.768). The negative value of such correlation does not indicate whether the substituent influence on antitumor activity is strong or not, but it only shows the direction of the effect. A negative value indicates correlation of a negative association, which means that the effect of one variable is inversely proportional to other variables. The relationship between the smallest independent variables is the qN8-qN13 (0.001) variable, which indicates that the qN8 variable and qN13 have a weaker relationship than other independent variables. Meanwhile, the relationship between the largest independent variables is variable qC7-qC5 (0.994) which shows that between variables qC7 and qC5, there is stronger relationship than other independent variables. Based on the bivariate correlation analysis, it can be concluded that between the independent variable and dependent variable, there is a significant relationship. Thus, MLR analysis can be performed on a group of the data in this research.

The MLR analysis on a group of independent variables as descriptor and dependent variable or antitumor activity (Log IC₅₀) produced a model of QSAR equation which is the best model of QSAR equation. The best QSAR model built using MLR method is represented by the following equation:

$$\text{Log IC}_{50} = -13.010 + 15.338(\text{qC3}) - 4.31(\text{qC4}) - 155.308(\text{qC9}) + 33.626(\text{qC11}) + 26.626(\text{qC12}) + 24.631(\text{qC14}) - 0.228(\mu) - 0.621(\text{ELUMO}) - 0.066(\alpha) + 0.233(\text{Log P}) \dots\dots\dots(3)$$

The statistical significance of the best QSAR models has coefficient correlation $n=11$, $(r)=1.00$, $(r^2)=1.00$, $\text{SE}=0$, and $\text{PRESS} = 0.003$.

To test the accuracy of the model of the obtained QSAR equation, it is necessary to calculate the IC₅₀ prediction value of the internal test compound (Table I). The proof of the accuracy of the model of QSAR equation can be seen on the graph of Log IC₅₀ value of prediction with an IC₅₀ value of the experimental internal test (compounds 1-11) (Figure 1). The graph shows the relationship between the Log IC₅₀ prediction value of the internal test compound and Log IC₅₀ experiment with obtained value $r^2 = 0.993$. The value of r^2 is close to 1, which indicates that the internal test model of QSAR equation has a very high level of trust.

To test the validity of the model of QSAR equation, a validity test has been performed by using external test compounds (compounds 12-15). The external test compound is a quinoacridinium compound derivative which has been known as IC₅₀ experimental value, but it is not included in the calculation process in determining QSAR equation model. This is intended to validate the QSAR model more accurately since it is validated with internal test compounds and external test compounds. The IC₅₀ value of external compound test (Table III).

The graphic of correlation between Log IC₅₀ calculated and Log IC₅₀ experiments value has $r^2=0.9701$ (Figure 2). It shows that the QSAR equation model obtained in this research is the best QSAR equation for determining the IC₅₀ value of compound derivative quinoacridinium. The high value of r^2 (close to 1) displayed in the correlation graph between Log IC₅₀ calculated from the external test compound and the Log IC₅₀ value of the experiments reinforces the QSAR model as an equation with high validity.

Based on the value of $r^2 = 0.9701$ obtained from the correlation between Log IC₅₀ of calculated from external test compound and Log IC₅₀ experiment, it proves that the relationship between calculated IC₅₀ value of external test compound and Log IC₅₀ value of experiment is very strong. Thus, it can be concluded that the model of QSAR equation obtained by using MLR analysis is very significant to determine the value of Log IC₅₀ compounds models of quinoacridinium derivatives.

Design of new antitumor quinoacridinium derivative compounds

The molecular design of the quinoacridinium derivative remains concerned with the active side of the homologous and atomic frameworks or the functional groups bound to the basic framework structure of the compound. The differences of atoms or functional groups bound to the basic frameworks of homologous compounds of quinoacridinium derivatives may cause different charges of atoms and differences in physical and chemical properties. In addition, it also causes differences in antitumor activity of such compounds (Hadanu *et al.*, 2015). The obvious that compounds which have different structures can produce different antitumor activity (Table I-V). Based on this fact, it can be concluded that different structures have electronic properties and molecular properties (different net charge of atoms and other descriptors). Compounds that have

Table V. Descriptors/independent of external standard for QSAR analysis of antitumor compounds of quinoacridinium derivatives calculated by the semi-empirical PM3 method

Comp. Number	Atomic net charges (Coulomb)												
	qC1	qC2	qC3	qC4	qC5	qC6	qC7	qN8	qC9	qC10	qC11	qC12	qN13
12	-0.032	-0.091	0.103	-0.136	-0.147	0.024	-0.182	0.188	-0.152	-0.062	0.059	-0.113	0.527
13	-0.083	-0.043	-0.112	-0.060	-0.152	-0.011	-0.185	0.171	-0.170	-0.030	-0.125	-0.045	0.565
14	-0.154	-0.011	-0.132	-0.050	-0.145	-0.017	-0.179	0.187	-0.173	-0.032	-0.115	-0.057	0.418
15	-0.002	-0.083	-0.096	-0.105	-0.142	-0.014	-0.176	0.172	-0.169	-0.029	-0.123	-0.045	0.577
Comp. Number	Atomic net charges (Coulomb)								μ	E_{LUMO}	E_{HOMO}	α	Log P
	qC14	qC15	qC16	qC17	qC18	qC19	qC20	qC21	(Debye)	(ev)	(ev)	(Å ³)	
12	-0.184	-0.006	0.047	0.013	-0.126	-0.104	-0.045	0.001	17.825	-2.485	-8.947	41.64	-0.57
13	-0.083	-0.076	0.072	0.011	-0.122	-0.121	-0.024	-0.007	12.141	-2.084	-5.097	42.12	-0.44
14	-0.093	-0.067	0.049	-0.005	-0.100	-0.111	-0.029	-0.015	12.211	-2.446	-5.288	51.38	1.24
15	-0.128	-0.020	0.053	0.005	-0.112	-0.120	-0.025	-0.010	13.966	-2.229	-5.155	42.70	1.05

different electronic and molecular properties absolutely produce different antitumor activity.

Based on the above explanation and QSAR model equations (3), atomic charge values of qC3, qC4, qC9, qC11, qC12, qC14, μ , E_{LUMO} , α , and Log P for respective designed compounds are variables influencing the value of antitumor activity (IC_{50}) of quinoacridinium derivatives. In designing the molecule, it is necessary to consider the attachment of the atom or functional groups to the main framework of quinoacridinium derivatives which can cause the change of atomic charge value of qC3, qC4, qC9, qC11, qC12, qC14, μ , E_{LUMO} , α , and Log P, so that it can cause different predictions of IC_{50} value (Table V). The calculation of atomic charges and other descriptors obtained from each of the new compounds is incorporated into the QSAR model of equation (3) in order to obtain theoretical IC_{50} values of the novel compound derived from the modeling design. Compounds that have a small IC_{50} value are antitumor compounds that have the highest antitumor activity. The smaller IC_{50} value of a quinoacridinium derivative compound is, the higher the chances of the compound as an antitumor drug is and it may be proposed for synthesis in the laboratory.

The calculated IC_{50} value of new molecules from the quinoacridinium derivatives design (Table VI and VII). Some compounds from quinoacridinium (Table VI and VII) derivative design are proposed for synthesis, in which they have an IC_{50} value smaller than IC_{50} of fifteen quinoacridinium derivatives (Tables I and II). Thus the quinoacridinium derivatives compounds derived from the recommended modeling design are: compounds 16 ($IC_{50}=0.000002\mu M$), 19 ($IC_{50}=0.125555\mu M$), 20 ($IC_{50}=0.173970\mu M$), 22

($IC_{50}=0.127722\mu M$), 23 ($IC_{50}=0.091970\mu M$), 24 ($IC_{50}=0.000118\mu M$), 25 ($IC_{50}=0.000398\mu M$), 26 ($IC_{50}=0.018086\mu M$), 27 ($IC_{50}=0.055728\mu M$), 28 ($IC_{50}=0.122898\mu M$), 30 ($IC_{50}=0.034668\mu M$), 31 ($IC_{50}=0.000004\mu M$), 32 ($IC_{50}=0.017990\mu M$), 39 ($IC_{50}=0.040617\mu M$), and 40 ($IC_{50}=0.156537\mu M$). Theoretically, they can be proposed for synthesis in the laboratory. Certainly, in the synthesis process in the laboratory, it is prioritized to synthesize compounds that have smaller IC_{50} values and compounds that have the easy synthesis pathways in the laboratory, as well as the availability of chemicals (Hadanu and Syamsudin, 2013; Hadanu *et al.*, 2015). The theoretical IC_{50} value of the quinoacridinium derivatives is less than the IC_{50} value determined by the National Cancer Institute (NCI) for the compounds extracted from the natural material. According to the National Cancer Institute (NCI), an extract is considered to have an active anticancer activity if its IC_{50} value is $<30\mu g/mL$, moderate active anticancer activity if its IC_{50} value is $\geq 30\mu g/mL$, $IC_{50}<100\mu g/mL$, and inactive anticancer activity if its IC_{50} value is $>100\mu g/mL$.²

Based on the structure model of the QSAR analysis recommended for synthesis in the laboratory, it can be concluded that the quinoacridinium derivatives which have high and potential antitumor activities are quinoacridinium derivatives which have functional groups as follows: -Cl is bound to C3 and C11 atoms; the -CH₃ function group is bound to C6, C8, and C13 atoms, anion H₃COSO₃⁻; -OCH₃ functional group is bound to C6 atom, anion iodide (I⁻); functional group of -CH=CHCON(CH₂CH₂)₂O is bound to C6 and C10 atoms; the functional group of -(CH₂)₃OCOCH₃ is bound to C3, C6, and C10; -C₂H₅ functional group is

bound to C13 atom, anion $\text{H}_5\text{C}_2\text{OSO}_3^-$. Those all are bound to the main framework of quinoacridinium compounds. Nearly all compounds modeled according to Lipinski's Rule are quinoacridinium derivative compounds having fewer than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or more hydrogen atoms), less than 10 hydrogen bond acceptors (nitrogen or oxygen atoms), and having an octanol-water partition coefficient (Log P) is less than 5.

CONCLUSION

Based on the results and discussion, it can be concluded that the best model of QSAR equation which shows the relationship between antitumor activity and latent variables to 11 compounds of quinoacridinium derivatives is: $\text{Log IC}_{50} = -13.010 + 15.338(\text{qC3}) - 4.31(\text{qC4}) - 155.308(\text{qC9}) + 33.626(\text{qC11}) + 26.626(\text{qC12}) + 24.631(\text{qC14}) - 0.228(\mu) - 0.621(\text{ELUMO}) - 0.066(\alpha) + 0.233(\text{Log P})$; $n = 11$, $(r) = 1.00$, $(r^2) = 1.00$, $\text{SE} = 0$, and $\text{PRESS} = 0.003$. A good correlation was observed between the experimental and predicted values of the anticancer activity ($R=0.993$), which indicated the validity and quality of the QSAR model developed in this work. Therefore, we conclude that the descriptors studied (e.g., atomic charge values qC3, qC4, qC9, qC11, qC12, qC14, μ , ELUMO , α , and Log P), which influenced the structural features of the quino-acridinium, can be used in tandem with other topological descriptors for the development of predictive QSAR models. The design of quinoacridinium derivative compounds which have high theoretical antitumor activity and are recommended for synthesizing in the laboratory are 16 of 28 compounds. Such designed compounds are 16, 19, 20, 22 to 28, 30, 32, 39, and 40.

REFERENCES

- Alam M., Khan A., Wadood A., Khan A., Bashir S., et al., 2016. Bioassay-guided isolation of sesquiterpene coumarins from *Ferula narthex* bioss: A new anticancer agent. *Frontiers in Pharmacology*, 7(FEB), 1–6. <https://doi.org/10.3389/fphar.2016.00026>
- Bladt TT., Frisvad JC., Knudsen PB., and Larsen TO. 2013. *Anticancer and antifungal compounds from Aspergillus, Penicillium and other filamentous fungi. Molecules* (Vol. 18). <https://doi.org/10.3390/molecules180911338>
- Bradley CJ., Yabroff KR., Dahman B., Feuer EJ., Mariotto A., and Brown ML. 2008. Productivity costs of cancer mortality in the United States: 2000–2020. *J. Nat. Canc. Institute*, 100(24), 1763–1770. <https://doi.org/10.1093/jnci/djn384>
- Cheng MK., Modi C., Cookson JC., Hutchinson I., Heald RA., et al., 2008. Antitumor polycyclic acridines. 20.1 Search for DNA quadruplex binding selectivity in a series of 8,13-dimethylquino[4,3,2-kl]acridinium salts: Telomere-targeted agents. *J. Medicinal Chemistry*, 51(4), 963–975. <https://doi.org/10.1021/jm070587t>
- Cookson JC., Heald RA., and Stevens MFG., 2005. Antitumor polycyclic acridines. 17. Synthesis and pharmaceutical profiles of pentacyclic acridinium salts designed to destabilize telomeric integrity. *J. Medicinal Chemistry*, 48(23), 7198–7207. <https://doi.org/10.1021/jm058031y>
- Deep A., Narasimhan B., Lim SM., Ramasamy K., Mishra RK., and Mani V., 2016. 4-Thiazolidinone derivatives: Synthesis, antimicrobial, anticancer evaluation and QSAR studies. *RSC Advances*, 6(111), 109485–109494. <https://doi.org/10.1039/c6ra23006g>
- Ferguson AM., Heritage T., Jonathon P., Pack SE., Phillips L., Rogan J. and Snaith PJ., 1997. EVA: A new theoretically based molecular descriptor for use in QSAR/QSPR analysis. *J. Computer-Aided Molecular Design*, 11(2), 143–152. <https://doi.org/10.1023/A:1008026308790>
- Florea AM. and Büsselberg D. 2011. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. *Cancers*, 3(1), 1351–1371. <https://doi.org/10.3390/cancers3011351>
- Fugmann B., Steffan B., and Steglich W., 1984. Necatorone, An Alkaloidal Pigment From The Gilled Toadstool *Lactarius Necator* (Agaricales). *Tetrahedron Letters*, 25(33), 3575–3578.
- Hadanu R., Idris S. and Sutapa IW. 2015. QSAR analysis of benzothiazole derivatives of antimalarial compounds based on AM1 semi-empirical method. *IJC.*, 15(1), 86–92. <https://doi.org/10.22146/ijc.21228>
- Hadanu R., and Syamsudin. 2013. Quantitative structure-activity relationship analysis of antimalarial compound of mangostin derivatives using regression linear approach. *Asian J. Chem.*, 25(11), 6136–6140.
- Hagan DJ., Chan D., Schwalbe H. and Stevens MFG.

- (1998). Antitumour polycyclic acridines . Part 3 . 1 A two-step conversion of 9-azidoacridine to 7 H -pyrido [4 , 3 , 2- kl] acridines by Graebe – Ullmann thermolysis of substituted 9- (1 , 2 , 3-triazol-1-yl) acridines, 915–923.
- Hagan DJ., Giménez-Arnau E., Schwalbe CH. and Stevens MFG. 1997. Antitumour polycyclic acridines. Part 1. Synthesis of 7H-pyrido- and 8H-quinolo-[4,3,2-kl]acridines by Graebe-Ullmann thermolysis of 9-(1,2,3-triazol-1-yl)acridines: Application of differential scanning calorimetry to predict optimum cyclisation conditions. *J. Chemical Society - Perkin Transactions 1*, (18), 2739–2746. <https://doi.org/10.1039/a702299i>
- Heliawati L., Kardinan A., Mayanti T. and Tjokronegoro R. 2015. Piceatanol: Anticancer compound from *Gewang* seed extract. *J Applied Pharmaceutical Science*, 5(1), 110–113. <https://doi.org/10.7324/JAPS.2015.50119>
- Hosny MA., Radwan HA. and El-Sawi EA. 2012. Synthesis and anticancer activity of some new derivatives of coumarin and quinolinyl mercaptotriazoles. *E-Journal of Chemistry*, 9(4), 1737–1745. <https://doi.org/10.1155/2012/365647>
- Julino M. and Stevens MFG. 1998. Antitumour polycyclic acridines. Part 5.1 Synthesis of 7H-pyrido[4,3,2-kl]acridines with exploitable functionality in the pyridine ring. *J the Chemical Society - Perkin Transactions 1*, (10), 1677–1684. <https://doi.org/10.1039/a800575c>
- Leonetti C. 2004. Biological Activity of the G-Quadruplex Ligand RHPS4 (3,11-Difluoro-6,8,13-trimethyl-8H-quinolo[4,3,2-kl]acridinium methosulfate) Is Associated with Telomere Capping Alteration. *Molecular Pharmacology*, 66(5), 1138–1146. <https://doi.org/10.1124/mol.104.001537>
- Luo Z.-H., He S.-Y., Chen B.-Q., Shi Y.-P., Liu Y.-M., Li C.-W., and Wang Q.-S. (2012). Synthesis and *in Vitro* Antitumor Activity of 1,3,4-Oxadiazole Derivatives Based on Benzoselenazone. *Chemical & Pharmaceutical Bulletin*, 60(7), 887–891. <https://doi.org/10.1248/cpb.c12-00250>
- Miladiyah I., Tahir I., Jumina J., Mubarika S. Mustofa M. 2016. Quantitative Structure-Activity Relationship Analysis of Xanthone Derivates as Cytotoxic Agents in Liver Cancer Cell Line HepG2. *Molekul*, 11(1), 143. <https://doi.org/10.20884/1.jm.2016.11.1.203>
- Missailidis S., Stanslas J., Modi C., Ellis MJ., Robins R. A., Laughton CA. and Stevens MFG. 2002. Antitumor Polycyclic Acridines . Part 12 . 1 Physical and Biological Properties A Lead Compound in Anticancer Drug Design, 13, 175–189.
- Mota LF., Gaudio AC. and Takahata Y., 2006. Quantitative Structure–Activity Relationships of a Series of Chalcone Derivatives (1,3-Diphenyl-2-propen-1-one) as Anti *Plasmodium falciparum* Agents (Anti Malaria Agents). *Internet Electronic Journal of Molecular Design*, 5(12), 555–569, <https://doi.org/10.1103/PhysRevLett.104.207002>
- Noolvi MN. and Patel HM. 2013. Synthesis, method optimization, anticancer activity of 2,3,7-trisubstituted Quinazoline derivatives and targeting EGFR-tyrosine kinase by rational approach. 1st Cancer Update. *Arabian Journal of Chemistry*, 6(1), 35–48. <https://doi.org/10.1016/j.arabjc.2010.12.031>
- Nugraha I., Annisa AN., Wibowo AT. and Kusuma A. M. 2018. Chemopreventive Activity of Kola (*Cola Accuminata*) Seed Ethanol Extract in Mice Induced by Cyclophosphamide. *IOP Conference Series: Materials Science and Engineering*, 288(1). <https://doi.org/10.1088/1757-899X/288/1/012008>
- Schmitt S. and Dou QP. 2013. Metal-Based Compounds as Proteasome-Inhibitory Anti-Cancer Drugs, 1(1), 1–3. <https://doi.org/10.4172/1000e101>
- Shelton J., Lu X., Hollenbaugh JA., Cho JH., Amblard, F. and Schinazi RF. 2016. Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs. *Chemical Reviews*, 116(23), 14379–14455. <https://doi.org/10.1021/acs.chemrev.6b00209>
- Stanslas J., Hagan DJ., Ellis MJ., Turner C., Carmichael J., Ward W., *et al.*, 2000. Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines. *Journal of Medicinal Chemistry*, 43(8), 1563–1572. <https://doi.org/10.1021/jm9909490>
- Su QG., Liu Y., Cai YC., Sun YL., Wang B. and Xian L. J. 2011. Anti-tumour effects of xanthone

- derivatives and the possible mechanisms of action. *Investigational New Drugs*, 29(6), 1230–1240.
<https://doi.org/10.1007/s10637-010-9468-5>
- Reddy TP. 2012. Exploring the Anti-inflammatory and Anti-cancer compounds \nfrom the leaves of *Acalypha indica*. *IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS)*, 4(2), 01–07. Retrieved from <http://www.iosrjournals.org/iosr-jpbs/pages/v4i2.html>
- Torre LA., Bray F., Siegel RL., Ferlay J., Lortet-Tieulent J. and Jemal A. 2015. Global Cancer Statistics, 2012. *Cancer Statistics CA Cancer J Clin*. <https://doi.org/10.3322/caac.21262>.
- Tripodi F., Pagliarin R., Fumagalli G., Bigi A., Fusi P., Orsini F. *et al.*, 2012. Synthesis and biological evaluation of 1,4-diaryl-2-azetidinones as specific anticancer agents: Activation of adenosine monophosphate activated protein kinase and induction of apoptosis. *Journal of Medicinal Chemistry*, 55(5), 2112–2124. <https://doi.org/10.1021/jm201344a>